BRCA1 and BRCA2: 1994 and beyond
By S. Narod, W. Foulkes. Nature Reviews. Cancer, 2004
1,014 citations recorded by the source corpus.
Subfields: Genetics, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/5e340a3f69b1a2b25a0747e26ddcaee241062fcc
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
- Oliver Kepp
- Guido Kroemer
- G. Lindeman
- Gordon K. Smyth
- E. Lengyel
- Jane E. Visvader
- Bradley Efron
- Yunshun Chen
In Molecular Biology
- Guido Kroemer
- L. Galluzzi
- Ryuji Hamamoto
- Yusuke Nakamura
- Oliver Kepp
- Jane E. Visvader
- Marie-Liesse Asselin-Labat
- M. Castedo
Citations in the corpus
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs (2008, background): “BRCA1 and BRCA2 function is critical for homologous recombination (HR) (6, 7), and BRCA-deficient cells appear to be highly sensitive to PARP inhibition, resulting in increased genomic instability, cell cycle arrest, and apoptosis (4, 5).”
- Homologous recombination and its regulation (2012, background): “Among the RAD51 regulators, heterozygous mutations in BRCA2 increase susceptibility to breast and ovarian cancers (292).”
- Molecular mechanisms of cisplatin resistance (2012, background): “Two critical components of the HR system are encoded by BRCA1 and BRCA2, two genes that are frequently mutated in familial breast and ovarian cancers (Venkitaraman, 2002; Narod and Foulkes, 2004).”
- Loss of BRCA1 in the cells of origin of ovarian cancer induces glycolysis: A window of opportunity for ovarian cancer chemoprevention (2017, background): “4F) and others have also reported binding of MYC to BRCA1 (30).”
- Surface Plasmon Resonance: A Versatile Technique for Biosensor Applications (2015, background): “Mutations in these two genes can lead to instability of the human genome and can increase the risk of breast cancer for future patients from the age of 30 [68].”
- Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers (2009, background): “Whereas multiple functions for BRCA1 have been described, such as in the DNA damage response, X-chromosome inactivation and transcriptional and cell cycle contro”